Clinical Trial Detail

NCT ID NCT03742895
Title Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

Therapies

Olaparib

Age Groups: adult senior

No variant requirements are available.